Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes

Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-onset T1D subjects aged 12–45 years is antithymocyte glob...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Simon Bond, David Dunger, Mark Wilson, Adrian Mander, Mikael Knip, Anita Chhabra, M Loredana Marcovecchio, Charlotte S Wilhelm-Benartzi, Michael J Haller, Timothy Tree, Hilde Morobé, Sarah E Miller, Sylvaine Bruggraber, Diane Picton, Katrina Gatley, A Emile J Hendriks, Bärbel Aschemeier-Fuchs, Lut Overbergh, Jaivier Pall, Olivier Arnaud, Almut Nitsche, Anke M Schulte
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2021-12-01
coleção:	BMJ Open
Acesso em linha:	https://bmjopen.bmj.com/content/11/12/e053669.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!